Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.

Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B.

JAMA. 2006 Sep 13;296(10):1242-8.

PMID:
16968848
2.
3.
4.
5.

Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials.

Devereux RB, Agabiti-Rosei E, Dahlöf B, Gosse P, Hahn RT, Okin PM, Roman MJ.

J Hypertens Suppl. 1996 Sep;14(2):S95-101; discussion S101-2. Review. Erratum in: J Hypertens 1997 Jan;15(1):103.

PMID:
8934385
6.

The prognostic value of the ECG in hypertension: where are we now?

Ang D, Lang C.

J Hum Hypertens. 2008 Jul;22(7):460-7. doi: 10.1038/jhh.2008.24. Epub 2008 Apr 24. Review.

PMID:
18432258
7.

Regression of left ventricular hypertrophy in hypertension--does it reduce cardiovascular risk?

Braz Nogueira J.

Rev Port Cardiol. 2005 Jul-Aug;24(7-8):1007-13. Review. English, Portuguese.

8.

Blood pressure variability and risk of new-onset atrial fibrillation: a systematic review of randomized trials of antihypertensive drugs.

Webb AJ, Rothwell PM.

Stroke. 2010 Sep;41(9):2091-3. doi: 10.1161/STROKEAHA.110.589531. Epub 2010 Jul 22. Review. Erratum in: Stroke. 2011 Oct;42(10):e569.

9.

The structural and electrical remodeling of myocardium in LVH and its impact on the QRS voltage.

Bacharova L.

Anadolu Kardiyol Derg. 2007 Jul;7 Suppl 1:37-42. Review.

10.

Anti-hypertensive drugs have different effects on ventricular hypertrophy regression.

Ferreira Filho C, Abreu LC, Valenti VE, Ferreira M, Meneghini A, Silveira JA, Riera AR, Colombari E, Murad N, Santos-Silva PR, Silva LJ, Vanderlei LC, Carvalho TD, Ferreira C.

Clinics (Sao Paulo). 2010 Jul;65(7):723-8. doi: 10.1590/S1807-59322010000700012. Review.

11.

Resistant hypertension and left ventricular hypertrophy: an overview.

Cuspidi C, Vaccarella A, Negri F, Sala C.

J Am Soc Hypertens. 2010 Nov-Dec;4(6):319-24. doi: 10.1016/j.jash.2010.10.003. Review.

PMID:
21130978
12.

Modulation of the QT interval duration in hypertension with antihypertensive treatment.

Klimas J, Kruzliak P, Rabkin SW.

Hypertens Res. 2015 Jul;38(7):447-54. doi: 10.1038/hr.2015.30. Epub 2015 Mar 19. Review.

PMID:
25787045
13.

Transthoracic echocardiography for evaluation of hypertensive heart disease.

Dellsperger KC.

Echocardiography. 1993 May;10(3):295-302. Review.

PMID:
10148636
14.

Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels.

Ogunsua AA, Shaikh AY, Ahmed M, McManus DD.

Methodist Debakey Cardiovasc J. 2015 Oct-Dec;11(4):228-34. doi: 10.14797/mdcj-11-4-228. Review.

15.

Atrial Fibrillation Predictors: Importance of the Electrocardiogram.

German DM, Kabir MM, Dewland TA, Henrikson CA, Tereshchenko LG.

Ann Noninvasive Electrocardiol. 2016 Jan;21(1):20-9. doi: 10.1111/anec.12321. Epub 2015 Nov 2. Review.

16.

Natriuretic peptides and the genomics of left-ventricular hypertrophy.

Dries DL.

Heart Fail Clin. 2010 Jan;6(1):55-64. doi: 10.1016/j.hfc.2009.08.007. Review.

17.

Risk Alteration for Atrial Fibrillation with DifferentAntihypertensive Drugs.

Barrios V, Escobar C.

J Atr Fibrillation. 2011 Dec 20;4(4):423. doi: 10.4022/jafib.423. eCollection 2011 Dec. Review.

18.

Prognostic significance of left ventricular hypertrophy regression.

Agabiti-Rosei E, Muiesan ML.

Adv Exp Med Biol. 1997;432:199-205. Review. No abstract available.

PMID:
9433527

Supplemental Content

Support Center